Our report is too lengthy for this space. Here is an intro and our conclusion. Read the full report: https://open.substack.com/pub/ruxtonparkresearch/p/off-the-hinges?r=4j7…
What does the company do?
Hinge uses a camera-enabled smartphone connected to Hinge’s AI-platform to support physical therapy and exercise related to MSK health. In addition to working with a physician and physical therapist (PT), Hinge’s program allows users to maximize their therapy and do so in the comfort of their own home, workplace, or anywhere else.
The best way to see the platform in action is to check out the company videos on the Hinge website or YouTube. It is really an amazing use case.
For example, let’s say a patient is recovering from knee surgery after a skiing accident. The therapy requires stretching and exercises. The patient launches the Hinge app, sets their phone up so it can “see” the patient, and then proceeds with their PT movements. The app tracks the patient and even offers real-time instruction and feedback to modify the movements.
All of this data is captured, analyzed, and builds on itself to become a better product over time.
Additionally, Hinge has launched other platforms as well such as female specific pelvic health programs and a medical device called Enso that supports pain reduction in muscles without the use of drugs.
For MSK, Hinge believes its product can replace 95% of the human interaction needed with PT.
The company sells primarily to large, self-insured employers either directly or through partners such as health insurers and pharmacy benefit managers. It counts half the Fortune 100 companies as customers. In a recent study, Hinge illustrate a 2.4x ROI for employers or cost savings of $2,387 per participant.
Hinge’s MSK platform would have been a great partner when I was rehabbing my injury. The platform looks to be an amazing technology for one of the biggest chronic health issues globally. Furthermore, the company is generating hundreds of millions in revenue. This all sounds great…
But – should we buy the stock? That is the real question we are exploring in this report.
Let’s dive a bit deeper into what is influencing our thoughts on this stock. This reminds us of a super-hyped healthcare IPO a decade ago.
After careful analysis, we would take Hinge Health IPO shares if allocated and look to harvest profits in early, euphoric trading. We would avoid buying shares in the open market for a period of time – perhaps weeks to months. Over this time, the stock will shake out, new information will emerge, and investors will quickly get a sense of what the market really thinks. That said, Hinge Health has the makings of a great healthcare technology stock at the right price.
Read the full report: https://open.substack.com/pub/ruxtonparkresearch/p/off-the-hinges?r=4j7…
